AMDL to Present its China Success Story at Rodman & Renshaw 9th Annual Healthcare Conference
October 22 2007 - 5:00AM
PR Newswire (US)
TUSTIN, Calif., Oct. 22 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi and Jilin, China, through its wholly owned
subsidiary Jade Pharmaceutical Inc. (JPI), is an international
biopharma company that engages in the development, manufacture and
marketing of proprietary pharmaceutical and diagnostic products.
AMDL announced today that its management will present on November
7, 2007, at the prestigious 9th Annual Healthcare Conference
sponsored by the full-service investment bank, Rodman &
Renshaw, and its life science division, Acumen BioFin(TM). The
presentation will be at 2:40 PM in the Kennedy I Room (4th floor).
"The Rodman & Renshaw conference, which annually presents more
than 350 companies to institutional investors, venture capitalists,
and sophisticated private investors, is a major opportunity for
AMDL to tell the story of its pharmaceutical successes in China,"
said Gary Dreher, CEO. Companies at the conference specialize in
cardiovascular diseases, drug delivery, gene therapy and oncology,
among other areas of investigation. The conference is November 5 -
7 at the New York Palace Hotel, 450 Madison Avenue, New York.
Information about the conference is available at Conference
Schedule: http://www.rodmanandrenshaw.com/us07conference under
"Program." About JPI: Jade Pharmaceutical has access to the fastest
growing pharmaceutical and consumer market in the world: China.
AMDL, through its subsidiary, Jade currently manufactures large
volume injectable fluids, tablets and other related products,
holding licenses for 133 products. It also manufactures 107
generic, over the counter and supplemental pharmaceutical products
under certified Chinese Good Manufacturing Practice (CGMP)
standards. About AMDL: More information about AMDL and its products
can be obtained at http://www.amdl.com/ . Forward-Looking
Statements This news release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements are subject to certain risks and
uncertainties, and actual circumstances, events or results may
differ materially from those projected in such forward-looking
statements. The Company cautions readers not to place undue
reliance on any forward-looking statements. The Company does not
undertake, and specifically disclaims any obligation, to update or
revise such statements to reflect new circumstances or
unanticipated events as they occur. Contact: AMDL, Inc. Mr. Paul
Knopick AMDL Investor Relations Direct Line: 949.707.5365
VoiceMail: 714.505.4460 DATASOURCE: AMDL, Inc. CONTACT: Mr. Paul
Knopick, AMDL Investor Relations, +1-949-707-5365, voicemail,
+1-714-505-4460, for AMDL, Inc. Web site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Sep 2023 to Sep 2024